Background Transcatheter closure of atrial septal defect (ASD) has been accepted as a standard treatment. There are diverse devices for transcathter closure of ASD. Occlutech Figulla Flex II (FSO) has been widely used for many reasons; especially such as an absent left atrial hub and flexible delivery system. We reported early experience of FSO device in Korea. Methods Since we adopted Occluech Figulla Flex II (FSO) for the first time in Korea in Sep. 2014, within two years (Between Sep. 2014 and Aug. 2016), total of 267 patients with secundum atrial septal defects underwent transcatheter closure in our institute. FSO was most commonly used in 152 (56.9%), followed by ASO (n=98, 36.7%) and by Gore Septal Occluder (GSO, n= 17, 6.4%). Baseline characteristics, hemodynamic features, comorbidities, success rate and complication rate were compared in three groups. Results Baseline characteristics and hemodynamic features are similar between groups, except the defect size and pulmonary flow-to-systemic flow (Qp/Qs) ratio was lower in the GSO groups as we expected. The procedural success rate was 100% in all groups, and major complication rate was less than 1%. In FSO group, 1 (0.9%) case of complete AV block, 3 (1.9%) patients of transient arrhythmia and 2 (1.4%) cases of hematoma, which were compatible to other two devices. There was no late complication of FSO device, although follow-up duration was limited. Conclusion In our early experience of FSO, we reported that transcatheter closure using FSO is feasible and safe. FSO device is an excellent option for transcatheter closure of ASD, especially when cardiac erosion is a concern.